6 reports

  • 6.3 MAJOR BRANDS - FIXED-DOSE COMBINATION DIRECT-ACTING ANTIVIRALS
  • 6.5 MAJOR BRANDS - PEGINTERFERON AND RIBAVIRIN

Potent antiviral activities of the direct-acting antivirals ABT-## and ABT-## with three-day monotherapy for hepatitis C virus Genotype ## infection.

  • Antiviral
  • Epidemiology
  • Hepatitis
  • Hepatitis Treatment
  • AbbVie Inc.

Top ## players hold majority of stake in the market ##.

  • Antiviral
  • Hepatitis
  • Hepatitis Treatment
  • Therapy
  • AbbVie Inc.

CHINA AND THE US ARE LEADING IN COUNTRY-SPECIFIC DRUG DEVELOPMENT. - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - Pre-registration ## ## Filing rejected/ Withdrawn Phase III ## ## ## ## Phase II ## ## ## Phase I ## ## ## ## Phase ## IND/ CTA Filed

  • Antiviral
  • Hepatitis
  • AbbVie Inc.
  • Gilead Sciences, Inc.
  • Merck & Co., Inc.

Hepatitis C

4385 5000 3900
  • DIRECT-ACTING ANTIVIRALS TARGET KEY VIRAL NON-STRUCTURAL PROTEINS NECESSARY FOR HCV REPLICATION
  • Pipeline: Hepatitis C

Antiviral Therapy [Epub ahead of print] < DOI> ##. ##/ IMP##< / DOI>.

  • Antiviral
  • Hepatitis
  • Hepatitis Treatment
  • Therapy
  • AbbVie Inc.
  • 3. Hepatitis C - Approved Drugs Sales & Forecast

This study will evaluate the safety, tolerability and antiviral efficacy of Sofosbuvir with Ribavirin (RBV) participants with genotype ## or ## Hepatitis C virus (HCV) infection who have chronic renal insufficiency.

  • Antiviral
  • Hepatitis
  • Hepatitis Treatment
  • Therapy
  • AbbVie Inc.
  • 6.2.2 PHASE II CLINICAL TRIALS ANALYSIS
  • 3. Hepatitis C - Approved Drugs Sales & Forecast to

Roche is developing mericitabine (R##), an investigational nucleoside inhibitor of NS##B HCV polymerase with antiviral activity against HCV genotypes ##-##.

  • Antiviral
  • Hepatitis
  • Hepatitis Treatment
  • Therapy
  • AbbVie Inc.